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Abstract Cell migration is a complex phenomenon that is
stimulated by chemoattractive factors such as chemokines, a
family of ligands for G protein-coupled receptors (GPCRs). In
contrast, factors that suppress cell migration, and the mecha-
nism of their action, remain largely unknown. In this study, we
show that endothelin, a GPCR ligand, inhibits cell motility in a
manner dependent upon signaling through the c-Jun N-terminal
kinase (JNK) pathway. We further demonstrate that this e¡ect
is dependent upon Src kinase and small GTPases Rac1 and
Cdc42. These ¢ndings provide new insight into GPCR-mediated
regulation of cell migration. . 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Cell migration is an important cellular process mediated by
extracellular ligands that bind and activate cell surface recep-
tors [1^5]. Such ligands include chemokines, which are chemo-
attractants that induce cell migration [1^4]. The cognate che-
mokine receptors comprise a subfamily of G protein-coupled
receptors (GPCRs) characterized by a heptahelical seven-
transmembrane structure [1^4].
In contrast to our understanding of the factors that induce
cell migration, ligands that inhibit this process are largely
unknown, with the exception of metastin and certain bioactive
lipids [6^12]. Metastin is a bioactive peptide derived from a
protein encoded by human melanoma metastasis suppressor
gene, KiSS-1, and has been identi¢ed as a ligand of certain
orphan GPCRs [6^9]. Bioactive lipids, such as sphingosine-1-
phosphate and platelet-activating factor, have been shown to
suppress cell motility and invasiveness, respectively, through
GPCRs [10^12].
Growing evidence suggests that GPCRs stimulate a signal-
ing pathway activating c-Jun N-terminal kinase (JNK), a sub-
family of mitogen-activated protein kinases (MAPKs) [13^18].
We and other groups have shown that the GPCR-JNK signal-
ing pathway involves tyrosine kinases and/or Rho family
small GTPases [13^18]. However, the physiological signi¢-
cance of the signaling pathway remains still unclear.
The endothelin receptor is a widely distributed GPCR that
has been implicated in pleiotropic functions [19,20]. Genetic
studies of the endothelin/endothelin receptor system suggest
an involvement in cell migration [19,20], although the detailed
function of endothelin in cell migration remains largely un-
known. In this study, we show that endothelin inhibits motil-
ity of human epithelial-like 293 cells. We also demonstrate
that endothelin-induced inhibition of cell motility is mediated
by the JNK signaling pathway. Furthermore, we investigate
the signaling mechanism controlling inhibition of cell motility
by endothelin.
2. Materials and methods
2.1. Materials
The following materials were employed in this study: anti-JNK
(C-17), anti-RhoA (26C4), and anti-Src (SRC2) from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA); anti-Rac1 (102) and
anti-Cdc42 (44) from BD Biosciences (San Jose, CA, USA); anti-
phosphorylated (pY418) Src (44^660) from BIOSOURCE Internation-
al (Nivelles, Belgium); anti-FLAG epitope (M2) from Sigma-Aldrich
Co. (St. Louis, MO, USA); anti-mouse and anti-rabbit IgG antibod-
ies conjugated with horseradish peroxidase from Amersham Bioscien-
ces (Buckinghamshire, UK); PP1 and PP2 from Biomol (Plymouth
Meeting, PA, USA); Clostridium di⁄cile toxin B from Calbiochem-
Novabiochem Co. (San Diego, CA, USA); endothelin-1 from Sigma-
Aldrich Co.
2.2. Plasmids
The mammalian expression plasmids encoding FLAG-tagged
MKK4K95R (dominant-inhibitory form of MKK4), constitutively
active (CA)-MEKK1, Rac1G12V (constitutively active form of
Rac1), and Cdc42G12V (constitutively active form of Cdc42) were
constructed as described previously [14^18,21]. The pUSE-CA-Src
plasmid was purchased from Upstate, Inc. (Lake Placid, NY, USA).
The Escherichia coli expression plasmids encoding the RhoA-binding
domain (RBD) of mDia1 and the Rac1- and Cdc42-binding domain
(CRIB) of KPak were constructed as described previously [17,22,23].
The pGEX2T-c-Jun (amino acids 1^221) plasmid was generously pro-
vided by M. Karin (University of California, San Diego, CA, USA).
2.3. Recombinant proteins
Recombinant GST-tagged mDia1RBD, KPakCRIB, and c-Jun pro-
teins were puri¢ed using E. coli BL21(DE3) pLysS, as described pre-
viously [17].
2.4. Cell culture and transfection
Maintenance of 293 cells and transient transfection (2 Wg of DNA
0014-5793 / 02 / $22.00 I 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 2 3 1 - 3
*Corresponding author. Fax: (81)-743-72 5449.
E-mail address: junyama@bs.aist-nara.ac.jp (J. Yamauchi).
FEBS 26457 30-8-02
FEBS 26457FEBS Letters 527 (2002) 284^288
per 6 cm dish) using Lipofectamine Plus (Invitrogen Co., Carlsbad,
CA, USA) were performed as described previously [17,18]. The me-
dium was replaced 24 h after transfection, and cells were starved in
serum-free medium for 24 h.
2.5. Cell migration assay
Cell migration was measured using a 24-well Boyden chamber (Bec-
ton Dickinson Labware, Franklin Lakes, NJ, USA), according to the
manufacturer’s protocol. Brie£y, upper wells with polyethylene ter-
ephthalate ¢lters (8 Wm pore size) were coated with 10 Wg/ml extra-
cellular matrix E-C-L (Upstate). Serum-starved cells (2U106 cells in
500 Wl of Dulbecco’s modi¢ed Eagle’s medium (DMEM) per well)
were loaded into upper wells, which were immediately plated on a
chamber containing 165 nM endothelin (750 Wl of DMEM per
well). After incubation at 37‡C for 3 h, upper ¢lters were stained
with a Di¡-Quick staining kit (International Reagents Co., Kobe,
Japan), according to the manufacturer’s protocol. Cells that had not
migrated were wiped away from the inner surface of the upper wells.
Using an optical microscope, the number of stained, migrated cells
was counted in at least three independent experiments.
2.6. JNK assay
Unless otherwise indicated, serum-starved cells were stimulated with
or without 100 nM endothelin for 5 min, and then lysed in lysis bu¡er
A (20 mM HEPES^NaOH (pH 7.5), 3 mM MgCl2, 100 mM NaCl,
1 mM dithiothreitol, 1 mM phenylmethane sulfonyl£uoride, 1 Wg/ml
leupeptin, 1 mM EGTA, 1 mM Na3VO4, 10 mM NaF, 20 mM L-glyc-
erophosphate, and 0.5% NP-40). Endogenous JNK was immunopre-
cipitated with an anti-JNK antibody, and the activity of JNK was
measured as the [32P]-radioactivity incorporated into recombinant
c-Jun, as described previously [14^18]. To estimate the amount of
JNK in the immunoprecipitates, we performed immunoblot analysis.
The band intensity of JNK in the immunoblot was semi-quanti¢ed
using NIH Image 1.61. Levels of radioactivity incorporated into c-Jun
Fig. 1. Endothelin inhibits cell motility through the JNK signaling pathway. A: 293 cells were treated with 100 nM endothelin for the indicated
times. The activity of endogenous JNK was measured by the amount of [32P]-radioactivity incorporated into recombinant c-Jun. B: Cells were
transiently transfected with the plasmid encoding mock or MKK4K95R. 48 h posttransfection, JNK activity was measured 5 min after the ad-
dition of 100 nM endothelin. C: Cells were transfected with the plasmid encoding mock or MKK4K95R. 48 h posttransfection, cell motility
was measured using a Boyden chamber. After incubation at 37‡C for 3 h with or without endothelin (100 nM, ¢nal concentration), cells at-
tached to the ¢lters were stained and analyzed under a microscope (upper photos). The number of stained, migrated cells was also counted
(lower ¢gure). D: Cells were transfected with the plasmid encoding mock, CA-MEKK1, or MKK4K95R. Cell motility was measured using a
Boyden chamber at 37‡C for 3 h.
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were normalized to the amount of immunoprecipitated JNK as esti-
mated from these band intensities.
2.7. Pull-down assays of Rho family small GTPases
Serum-starved cells were stimulated with or without 100 nM endo-
thelin for 5 min, and then lysed in lysis bu¡er B (50 mM HEPES^
NaOH (pH 7.5), 20 mM MgCl2, 150 mM NaCl, 1 mM dithiothreitol,
1 mM phenylmethane sulfonyl£uoride, 1 Wg/ml leupeptin, 1 mM
EDTA, 1 mM Na3VO4, 10 mM NaF, and 0.5% NP-40). To detect
endogenous GTP-bound Rho family small GTPases in the cell lysate,
we performed pull-down assays using recombinant GST-tagged
mDia1RBD (for RhoA) and KPakCRIB (for Rac1 and Cdc42) as
described previously [17,22,23]. Cell lysates were subjected to immu-
noblot analysis to estimate the amount of small GTPases. Represen-
tative results from three separate experiments are shown in Fig. 3.
2.8. Statistical analysis
Statistical analysis was performed using SAS StatView 5.0. Values
shown represent the meanSS.E.M. from at least three separate ex-
periments. Student’s t-test was carried out for intergroup comparisons
(*, P6 0.01).
3. Results and discussion
3.1. Endothelin inhibits cell motility through the JNK pathway
We previously showed that in 293 cells transfected transi-
ently with the plasmids encoding cDNAs of adrenergic and
muscarinic acetylcholine receptors, receptor stimulation acti-
vates JNK through the JNK kinase MKK4 [14, 17,18]. We
¢rst examined whether endothelin treatment activates JNK in
293 cells, which express the endothelin receptor natively [24].
We have detected that endothelin type A and type B receptors
express and the type A receptor mainly expresses in 293 cells,
using the method of reverse transcriptase-polymerase chain
reaction (data not shown). This result is consistent with the
result of Howard et al. [24]. As shown in Fig. 1A, endothelin
treatment of cells activated JNK in a time-dependent manner.
Next, we con¢rmed that MKK4K95R blocks endothelin-in-
duced JNK activation. MKK4K95R is a kinase-de¢cient var-
iant that inhibits transmission of signals from GPCRs to JNK
[14,16^18]. As shown in Fig. 1B, transfection of the plasmid
encoding MKK4K95R blocked JNK activation by endothe-
lin. These results suggested that the JNK cascade was acti-
vated in 293 cells by endothelin acting through its cognate
GPCR.
To examine the e¡ect of endothelin on cell motility, we
carried out the assay using Boyden chamber [5^7,10,11]. As
shown in Fig. 1C, endothelin treatment of cells signi¢cantly
inhibited cell motility in this assay. As far as we know, this is
the ¢rst report of inhibition of cell motility by endothelin.
Transfection of the plasmid encoding MKK4K95R blocked
endothelin-induced inhibition of cell motility (Fig. 1C), sug-
gesting that the JNK signaling cascade mediated the e¡ect of
endothelin on cell motility. Constitutively active (CA)-
MEKK1 is an isolated kinase domain of JNK kinase kinase
MEKK1 and acts as an activator of the JNK cascade [21].
Transfection of the plasmid encoding CA-MEKK1 suppressed
Fig. 2. Src kinase mediates endothelin-induced JNK activation.
A: Cells were pretreated with or without 10 WM PP1 for 18 h. JNK
activity was measured 5 min after the addition of 100 nM endothe-
lin. B: The autophosphorylation of Src was assessed 5 min after the
addition of 100 nM endothelin, using an antibody speci¢c for phos-
phorylated (pY418) Src. Levels of Src protein were measured by im-
munoblot analysis with an antibody that recognizes total Src pro-
tein.
Fig. 3. Rac1 and Cdc42 mediate endothelin-induced JNK activation.
A: Cells were pretreated with or without 2 ng/ml toxin B for 18 h.
JNK activity was measured 5 min after the addition of 100 nM en-
dothelin. B: Cells were pretreated with or without 10 WM PP1 for
18 h. The activity of Rho family small GTPases was measured 5 min
after the addition of 100 nM endothelin by pull-down assay using
recombinant mDia1RBD or KPakCRIB. Levels of Rho family small
GTPases in the cell lysates were estimated by immunoblot analysis.
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cell motility and this e¡ect was blocked by co-transfection of
MKK4K95R (Fig. 1D). These results further supported the
idea that endothelin inhibits cell motility through the JNK
signaling cascade.
3.2. JNK activation by endothelin is mediated by Src kinase
It has been reported that Src kinase mediates JNK activa-
tion induced by certain GPCRs [14,15,17]. Therefore, we ex-
amined the involvement of Src kinase in endothelin-induced
JNK activation. As shown in Fig. 2A, pretreatment of cells
with PP1, a speci¢c inhibitor of Src kinase, inhibited endothe-
lin-induced JNK activation. Similarly, JNK activation by en-
dothelin was blocked by pretreatment of cells with PP2, an-
other inhibitor of Src kinase (data not shown). We next
determined whether endothelin treatment of cells results in
activation of Src kinase, using an antibody speci¢c for the
autophosphorylated Src. We detected activation of Src, as
demonstrated by its autophosphorylation at Tyr418, in re-
sponse to endothelin treatment (Fig. 2B). These results sug-
gested that Src kinase mediates activation of JNK by endo-
thelin.
3.3. JNK activation by endothelin is mediated by Rac1 and
Cdc42
GPCR-mediated activation of JNK has been shown to in-
volve small GTPases of the Rho family [13^17]. Thus, we
examined the involvement of these small GTPases in endothe-
lin-induced JNK activation. C. di⁄cile toxin B glycosylates
Rho family small GTPases RhoA, Rac1, and Cdc42, and in-
hibits their cellular functions. Pretreatment of cells with toxin
B suppressed endothelin-induced JNK activation (Fig. 3A).
Next, we measured the intrinsic activities of Rho family small
Fig. 4. Endothelin-induced inhibition of cell motility requires the JNK pathway and is dependent upon Src kinase, Rac1, and Cdc42. A: Cells
were pretreated with or without 10 WM PP1 for 18 h, and then treated with or without endothelin (100 nM, ¢nal concentration) at 37‡C for
3 h. B: Cells were pretreated with or without 2 ng/ml toxin B for 18 h, and treated with or without endothelin (100 nM, ¢nal concentration)
at 37‡C for 3 h. C: Cells were transfected with the plasmid encoding mock, CA-Src, or MKK4K95R. D: Cells were transfected with the plas-
mid encoding mock, Rac1G12V, or MKK4K95R. E: Cells were transfected with or without the plasmid encoding mock, Cdc42G12V, or
MKK4K95R. Cell motility was measured using a Boyden chamber.
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GTPases by pull-down assays, using GST-tagged mDia1RBD
and KPakCRIB. mDia1RBD speci¢cally interacts with active
GTP-bound RhoA [22], and KPakCRIB speci¢cally associates
with active GTP-bound Rac1 or Cdc42 [23]. KPakCRIB
bound both Rac1 and Cdc42 from extracts prepared from
endothelin-treated cells, but mDia1RBD did not bind
RhoA, suggesting that endothelin activated Rac1 and
Cdc42, but not RhoA (Fig. 3B). Furthermore, pretreatment
of cells with PP1 inhibited endothelin-induced activation of
Rac1 and Cdc42 (Fig. 3B). These results suggested that endo-
thelin activates JNK through Rac1 and Cdc42, and that this
e¡ect is dependent upon active Src kinase.
3.4. Endothelin inhibits cell motility through the JNK pathway
in a manner dependent upon Src kinase, Rac1, and Cdc42
We next investigated whether Src kinase, Rac1, and Cdc42
participate in endothelin-induced inhibition of cell motility.
As shown in Fig. 4A, pretreatment of cells with PP1 sup-
pressed endothelin-induced inhibition of cell motility. Simi-
larly, pretreatment of cells with toxin B also reduced endothe-
lin-induced inhibition of cell motility (Fig. 4B). These results
suggested that active Src kinase and Rho family small
GTPases are necessary for inhibition of cell motility by endo-
thelin.
We further examined the e¡ect of Src kinase, Rac1, and
Cdc42 on cell motility through transfection studies making
use of a constitutively active form of these signaling compo-
nents. Transfection of constitutively active (CA)-Src inhibited
cell motility (Fig. 4C). Co-transfection of CA-Src with
MKK4K95R counteracted this e¡ect, demonstrating that
Src kinase inhibits cell motility in a manner dependent upon
the JNK pathway (Fig. 4C). Similarly, transfection of
Rac1G12V and Cdc42G12V, which are constitutively active
forms of Rac1 and Cdc42, respectively, inhibited cell motility
(Fig. 4D and E). Once again, this e¡ect was blocked by co-
transfection with MKK4K95R, demonstrating a dependence
upon the JNK pathway (Fig. 4D and E). Taken together,
these results suggested that endothelin inhibits cell motility
through the JNK pathway in a manner dependent upon Src
kinase, Rac1, and Cdc42.
Rac1 has been implicated in migration of cells such as ¢-
broblasts and endothelial cells [25^28]. In addition, a domi-
nant-inhibitory form of Cdc42 blocks the migration of macro-
phages [29]. These ¢ndings suggest that Rac1 and Cdc42
induce cell migration in certain types of cells. We have dem-
onstrated the involvement of Rac1 and Cdc42 in endothelin-
mediated inhibition of cell motility in 293 cells. The e¡ect of
Rac1 and Cdc42 on cell migration may vary, depending on
the cell type.
In this study, we have shown that endothelin inhibits cell
motility through activation of the JNK pathway in a manner
dependent upon Src kinase, Rac1, and Cdc42. Further study
is necessary to clarify how the endothelin receptor suppresses
cell motility. Such studies should enhance our understanding
of the general mechanism by which GPCRs regulate the JNK
pathway and in turn cell migration.
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